Every 8-K that Aclarion, Inc. (ACON) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ACON and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACON filings page.
Aclarion, Inc. reported the results of its 2026 annual meeting of stockholders. Stockholders elected seven directors to serve until the 2027 annual meeting, with each nominee receiving more votes for than withheld.
Stockholders also ratified the appointment of Haynie & Company as the company’s independent registered public accounting firm, with 1,588,388 votes for, 20,623 against, and 10,985 abstaining. In addition, an amendment to Aclarion’s 2022 equity incentive plan was approved, receiving 453,431 votes for, 323,512 against, 1,302 abstentions, and 841,751 broker non-votes.
Aclarion, Inc. has authorized a stock repurchase program of up to $2.5 million of its outstanding common shares. The company expects to carry out repurchases over the next 12 months, using methods such as open market purchases, block trades, privately negotiated deals, and 10b5-1 plans.
Aclarion plans to fund the program with existing cash and cash equivalents. As of March 31, 2026, it held approximately $19.0 million in cash and cash equivalents, which management believes is sufficient to support operations through key milestones, including the initial milestone of the CLARITY randomized trial.
Management describes the buyback as part of disciplined capital allocation and states they believe the current share price does not fully reflect the company’s Nociscan platform and long-term growth opportunity. The program is flexible and may be suspended, modified, or discontinued at any time.
Aclarion, Inc. adopted a limited-duration stockholder rights plan that issues one right for each share of common stock and each Rights-Eligible Warrant outstanding as of March 30, 2026. Each right lets holders buy one one-thousandth of a share of Series D Junior Participating Preferred Stock at $14.00, subject to adjustment.
The plan is triggered if a person or group acquires 10% or more of common stock without board approval, with existing holders at or above that level grandfathered so long as they do not increase ownership. If triggered, other holders can buy securities at a 2x value multiple, diluting the acquirer.
The plan expires on March 18, 2027 unless earlier redeemed for $0.001 per right, exchanged into common or preferred shares, or terminated in connection with a board-approved merger. Aclarion also designated 10,000 shares of Series D Junior Participating Preferred Stock to support the plan.
Aclarion, Inc. reported that it has closed a previously disclosed registered direct offering of its common stock and pre-funded warrants. Under a Securities Purchase Agreement dated January 8, 2026, the company agreed to sell 200,000 shares of common stock at a price of $5.18 per share, or pre-funded warrants in lieu of shares, and pre-funded warrants to purchase up to 1,800,000 additional shares of common stock. The company stated in a January 13, 2026 press release that this offering closed on January 9, 2026.
Aclarion, Inc. entered into a Securities Purchase Agreement for a registered direct offering of 200,000 shares of common stock at $5.18 per share and pre-funded warrants to purchase up to 1,800,000 additional shares. The pre-funded warrants are immediately exercisable at an exercise price of $0.00001 per share and remain exercisable until fully exercised, subject to beneficial ownership caps of 4.99% or 9.99% unless adjusted with 61 days’ notice.
The company expects gross proceeds of about $10.36 million before fees and expenses and may receive nominal additional proceeds from any cash exercises of the pre-funded warrants. Aclarion plans to use net proceeds to fund market development and clinical evidence, The Clarity Trial, product development and quality, and general and administrative support and other general corporate purposes.
Aclarion, Inc. entered into a Securities Purchase Agreement for a registered direct offering, selling 64,000 shares of common stock at $8.36 per share and issuing pre-funded warrants to purchase up to 236,000 shares. The company expects approximately $2.5 million in gross proceeds, with closing anticipated on or about October 14, 2025, subject to customary conditions.
The pre-funded warrants are immediately exercisable at an exercise price of $0.00001 and include a beneficial ownership cap of 4.99% or 9.99%, adjustable with 61 days’ prior notice. Dawson James Securities is the exclusive placement agent and will receive a 7.0% cash fee on gross proceeds plus expense reimbursement. Aclarion plans to use net proceeds to fund market development and clinical evidence, The Clarity Trial, product development and quality, and general and administrative support, and other general corporate purposes.